Zealand Pharma A/S (ZLDPF)
USD 75.15
(6.85%)
USD 75.15
(6.85%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 1.97 Billion DKK | 28.59% |
| 2022 | 1.53 Billion DKK | -25.53% |
| 2021 | 2.06 Billion DKK | 7.43% |
| 2020 | 1.92 Billion DKK | 20.32% |
| 2019 | 1.59 Billion DKK | 30.06% |
| 2018 | 1.22 Billion DKK | 66.81% |
| 2017 | 737.23 Million DKK | 6.13% |
| 2016 | 694.62 Million DKK | 9.44% |
| 2015 | 634.68 Million DKK | 6.36% |
| 2014 | 596.75 Million DKK | 72.02% |
| 2013 | 346.91 Million DKK | -33.41% |
| 2012 | 520.98 Million DKK | 10.97% |
| 2011 | 469.48 Million DKK | 4.2% |
| 2010 | 450.55 Million DKK | 183.94% |
| 2009 | 158.67 Million DKK | -29.55% |
| 2008 | 225.24 Million DKK | -14.48% |
| 2007 | 263.36 Million DKK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 10.15 Billion DKK | 183.14% |
| 2024 Q1 | 3.58 Billion DKK | 81.15% |
| 2023 FY | 1.97 Billion DKK | 28.59% |
| 2023 Q3 | 2.17 Billion DKK | 6.14% |
| 2023 Q2 | 2.04 Billion DKK | 52.9% |
| 2023 Q1 | 1.34 Billion DKK | -12.94% |
| 2023 Q4 | 1.97 Billion DKK | -8.99% |
| 2022 Q1 | 1.83 Billion DKK | -11.14% |
| 2022 FY | 1.53 Billion DKK | -25.53% |
| 2022 Q4 | 1.53 Billion DKK | 41.06% |
| 2022 Q3 | 1.09 Billion DKK | -13.13% |
| 2022 Q2 | 1.25 Billion DKK | -31.61% |
| 2021 Q2 | 1.92 Billion DKK | -11.32% |
| 2021 FY | 2.06 Billion DKK | 7.43% |
| 2021 Q4 | 2.06 Billion DKK | 24.5% |
| 2021 Q3 | 1.66 Billion DKK | -13.69% |
| 2021 Q1 | 2.16 Billion DKK | 12.74% |
| 2020 Q1 | 1.56 Billion DKK | -2.37% |
| 2020 Q3 | 2.05 Billion DKK | -9.36% |
| 2020 Q4 | 1.92 Billion DKK | -6.53% |
| 2020 FY | 1.92 Billion DKK | 20.32% |
| 2020 Q2 | 2.27 Billion DKK | 45.48% |
| 2019 Q3 | 1.71 Billion DKK | 39.38% |
| 2019 Q1 | 1.35 Billion DKK | 9.82% |
| 2019 Q2 | 1.22 Billion DKK | -8.97% |
| 2019 FY | 1.59 Billion DKK | 30.06% |
| 2019 Q4 | 1.59 Billion DKK | -6.66% |
| 2018 Q4 | 1.22 Billion DKK | -19.26% |
| 2018 Q2 | 522.13 Million DKK | -15.85% |
| 2018 FY | 1.22 Billion DKK | 66.81% |
| 2018 Q1 | 620.49 Million DKK | -15.83% |
| 2018 Q3 | 1.52 Billion DKK | 191.7% |
| 2017 Q4 | 737.23 Million DKK | -11.03% |
| 2017 FY | 737.23 Million DKK | 6.13% |
| 2017 Q3 | 828.62 Million DKK | 117.45% |
| 2017 Q2 | 381.06 Million DKK | -19.64% |
| 2017 Q1 | 474.2 Million DKK | -31.73% |
| 2016 Q1 | 534.94 Million DKK | -15.71% |
| 2016 FY | 694.62 Million DKK | 9.44% |
| 2016 Q4 | 694.62 Million DKK | 21.93% |
| 2016 Q3 | 569.7 Million DKK | 19.32% |
| 2016 Q2 | 477.45 Million DKK | -10.75% |
| 2015 Q2 | 516.82 Million DKK | -9.21% |
| 2015 FY | 634.68 Million DKK | 6.36% |
| 2015 Q3 | 535.74 Million DKK | 3.66% |
| 2015 Q1 | 569.23 Million DKK | -4.61% |
| 2015 Q4 | 634.68 Million DKK | 18.47% |
| 2014 Q3 | 357.77 Million DKK | 7.41% |
| 2014 FY | 596.75 Million DKK | 72.02% |
| 2014 Q4 | 596.75 Million DKK | 66.8% |
| 2014 Q2 | 333.09 Million DKK | -12.72% |
| 2014 Q1 | 381.66 Million DKK | 10.02% |
| 2013 FY | 346.91 Million DKK | -33.41% |
| 2013 Q1 | 470.96 Million DKK | -9.6% |
| 2013 Q4 | 346.91 Million DKK | -10.09% |
| 2013 Q3 | 385.83 Million DKK | -10.83% |
| 2013 Q2 | 432.71 Million DKK | -8.12% |
| 2012 Q3 | 564.08 Million DKK | 0.96% |
| 2012 Q1 | 553.36 Million DKK | 17.87% |
| 2012 Q4 | 520.98 Million DKK | -7.64% |
| 2012 Q2 | 558.71 Million DKK | 0.97% |
| 2012 FY | 520.98 Million DKK | 10.97% |
| 2011 FY | 469.48 Million DKK | 4.2% |
| 2011 Q3 | 485.13 Million DKK | -5.51% |
| 2011 Q1 | 408.81 Million DKK | -9.26% |
| 2011 Q2 | 513.41 Million DKK | 25.59% |
| 2011 Q4 | 469.48 Million DKK | -3.23% |
| 2010 Q4 | 450.55 Million DKK | 0.0% |
| 2010 FY | 450.55 Million DKK | 183.94% |
| 2009 FY | 158.67 Million DKK | -29.55% |
| 2008 FY | 225.24 Million DKK | -14.48% |
| 2007 FY | 263.36 Million DKK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Bioxytran, Inc. | 137.63 Thousand USD | -1438451.127% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | -4996.901% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -2593075.21% |
| SQZ Biotechnologies Company | 107.18 Million USD | -1747.232% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -138164.578% |
| Evofem Biosciences, Inc. | 10.55 Million USD | -18660.593% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | -1420.606% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -2736019.671% |
| Marizyme, Inc. | 22.01 Million USD | -8893.805% |
| Genus plc | 1.02 Billion USD | -92.438% |
| Pharming Group N.V. | 462.85 Million USD | -327.779% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -59664.136% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -396661.175% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -315688.357% |
| ContraFect Corporation | 20.67 Million USD | -9474.897% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -517982.721% |
| IMV Inc. | 31.33 Million USD | -6219.035% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -47656.452% |
| ONE Bio Corp. | 70.08 Million USD | -2725.111% |
| RVL Pharmaceuticals plc | 128.51 Million USD | -1440.731% |
| Mesoblast Limited | 667.9 Million USD | -196.45% |
| MultiCell Technologies, Inc. | 126.22 USD | -1568683943.733% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | -5528.338% |
| Genscript Biotech Corporation | 3.38 Billion USD | 41.531% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -256827.064% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -757713.738% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -27324.63% |
| Biomind Labs Inc. | 73.81 Thousand USD | -2682126.798% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -136560.287% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | -6496.689% |
| Skye Bioscience, Inc. | 11.94 Million USD | -16482.285% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -145664.245% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -71995.83% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -507114.512% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -101013.478% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -287904.847% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -210607.266% |
| EV Biologics, Inc. | 431.71 Thousand USD | -458535.347% |
| Q BioMed Inc. | 3.51 Million USD | -56221.531% |
| GB Sciences, Inc. | 103.44 Thousand USD | -1914009.356% |
| Alpha Cognition Inc. | 2.45 Million USD | -80644.524% |
| CSL Limited | 38.02 Billion USD | 94.793% |
| Agentix Corp. | 261.39 Thousand USD | -757380.336% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | -343.637% |
| Enzolytics Inc. | 361.7 Million USD | -447.403% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Resverlogix Corp. | 8.11 Million USD | -24299.174% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -105337.674% |
| MetaStat, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -75960.082% |
| argenx SE | 4.54 Billion USD | 56.411% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | -6985.575% |
| HST Global, Inc. | 1526.00 USD | -129750424.246% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | -4050.755% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -200310.844% |
| Halberd Corporation | 10.13 Thousand USD | -19543804.847% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -309440.284% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | -22024.916% |
| Zenith Capital Corp. | 7410.00 USD | -26720453.306% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -8691322.677% |
| GeneThera, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -615175.352% |
| AVAX Technologies, Inc. | 7.37 Million USD | -26739.513% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -757461.485% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -213270.282% |
| Ember Therapeutics, Inc. | 184.00 USD | -1076083052.174% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 62.24 Thousand USD | -3180713.841% |
| Helix BioMedix, Inc. | 3.02 Million USD | -65352.453% |
| Capstone Therapeutics Corp. | 52.7 Million USD | -3657.031% |
| Kadimastem Ltd | 2.3 Million USD | -85834.212% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 14.56 Million USD | -13498.581% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -3467852.85% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -85713882.684% |
| LadRx Corporation | 2.3 Million USD | -85692.645% |
| Cell Source, Inc. | 195.17 Thousand USD | -1014391.395% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -411920.426% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -559825.852% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -559825.852% |
| Affymax, Inc. | 7.44 Million USD | -26502.082% |
| Mobile Lads Corp. | 52.00 USD | -3807678746.154% |
| Itoco Inc. | 1.4 Million USD | -141320.798% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -2069788.247% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -1867817.925% |
| International Stem Cell Corporation | 5.39 Million USD | -36634.564% |
| CytoDyn Inc. | 11.13 Million USD | -17680.11% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -1384781.655% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -11073686.353% |
| Qrons Inc. | 420.00 USD | -471426804.762% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -513555.502% |
| SYBLEU INC | 330.46 Thousand USD | -599048.178% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -358516.424% |
| Rebus Holdings, Inc. | 5000.00 USD | -39599760.0% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -483506.89% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | -13098.343% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | -11842.777% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -2506220.253% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -228886.431% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -26240.202% |
| Neutra Corp. | 2851.00 USD | -69448970.502% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -6009.958% |
| PureTech Health plc | 693.97 Million USD | -185.313% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -24431.919% |
| IXICO plc | 15.84 Million USD | -12396.877% |
| IntelGenx Technologies Corp. | 8.28 Million USD | -23807.184% |
| Gelesis Holdings, Inc. | 103.32 Million USD | -1816.295% |
| CSL Limited | 38.02 Billion USD | 94.793% |
| Cellectis S.A. | 333.99 Million USD | -492.822% |